Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat vs Handihaler Preference in COPD
NCT03964207Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Performance Domain of the Patient Satisfaction and Preference Questionnaire (PASAPQ) at 8 weeks. Started Nov 2019; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03964207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964207.